New combo therapy aims to spare organs in High-Risk rectal cancer

NCT ID NCT07551479

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether short-course radiation followed by chemotherapy and an immunotherapy drug (serplulimab) works better than standard long-course chemoradiation for high-risk locally advanced rectal cancer. 612 patients will be randomly assigned to one of the two treatments. The goal is to improve event-free survival and increase the chance of avoiding surgery (organ preservation).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Short-course radiation, capecitabine, oxaliplatin, serplulimab (PD-1 inhibitor)
What this could lead to: If successful, this could offer a more effective, organ-sparing treatment option for high-risk rectal cancer patients, potentially avoiding surgery.
What could go wrong: This is an early phase 3 trial not yet recruiting. The combination may cause more side effects, and the long-term benefits over standard care are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Marinesco-Sjogren syndrome rectal cancer Spinocerebellar Degenerations

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RECTAL CANCER (LARC) MSS (MICROSATELLITE STABLE)

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.